| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ... The lancet oncology 15 (7), 700-712, 2014 | 1555 | 2014 |
| Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine) AM Bergman, HM Pinedo, GJ Peters Drug Resistance Updates 5 (1), 19-33, 2002 | 414 | 2002 |
| Basis for effective combination cancer chemotherapy with antimetabolites GJ Peters, CL Van der Wilt, CJA Van Moorsel, JR Kroep, AM Bergman, ... Pharmacology & therapeutics 87 (2-3), 227-253, 2000 | 391 | 2000 |
| Interaction between cisplatin and gemcitabine in vitro and in vivo. GJ Peters, AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper, ... Seminars in oncology 22 (4 Suppl 11), 72-79, 1995 | 384 | 1995 |
| Synergistic interaction between cisplatin and gemcitabine in vitro. AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper, GJ Peters Clinical cancer research: an official journal of the American Association …, 1996 | 361 | 1996 |
| Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines CJA Van Moorsel, HM Pinedo, G Veerman, AM Bergman, CM Kuiper, ... British journal of cancer 80 (7), 981-990, 1999 | 322 | 1999 |
| In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant AM Bergman, PP Eijk, VWT Ruiz van Haperen, K Smid, G Veerman, ... Cancer research 65 (20), 9510-9516, 2005 | 249 | 2005 |
| Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ... LIPPINCOTT WILLIAMS & WILKINS, 2016 | 232 | 2016 |
| Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines AM Bergman, HM Pinedo, I Talianidis, G Veerman, WJP Loves, ... British journal of cancer 88 (12), 1963-1970, 2003 | 200 | 2003 |
| Prostate cancer reactivates developmental epigenomic programs during metastatic progression MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ... Nature genetics 52 (8), 790-799, 2020 | 184 | 2020 |
| The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact LF van Dessel, J van Riet, M Smits, Y Zhu, P Hamberg, ... Nature communications 10 (1), 5251, 2019 | 163 | 2019 |
| Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone … S Badrising, V van der Noort, IM van Oort, HP van den Berg, M Los, ... Cancer 120 (7), 968-975, 2014 | 158 | 2014 |
| Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of … K Fizazi, CG Drake, TM Beer, ED Kwon, HI Scher, WR Gerritsen, A Bossi, ... European urology 78 (6), 822-830, 2020 | 125 | 2020 |
| Integrative epigenetic taxonomy of primary prostate cancer S Stelloo, E Nevedomskaya, Y Kim, K Schuurman, E Valle-Encinas, ... Nature communications 9 (1), 4900, 2018 | 117 | 2018 |
| Combination chemotherapy studies with gemcitabine. CJ Van Moorsel, G Veerman, AM Bergman, A Guechev, JB Vermorken, ... Seminars in oncology 24 (2 Suppl 7), S7-17, 1997 | 116 | 1997 |
| Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines AM Bergman, CM Kuiper, DA Voorn, EM Comijn, F Myhren, ML Sandvold, ... Biochemical pharmacology 67 (3), 503-511, 2004 | 113 | 2004 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 107 | 2023 |
| CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis MA Augello, D Liu, LD Deonarine, BD Robinson, D Huang, S Stelloo, ... Cancer Cell 35 (4), 603-617. e8, 2019 | 107 | 2019 |
| Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models AM Bergman, AD Adema, J Balzarini, S Bruheim, I Fichtner, P Noordhuis, ... Investigational new drugs 29, 456-466, 2011 | 104 | 2011 |
| Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis S Stelloo, E Nevedomskaya, Y Kim, L Hoekman, OB Bleijerveld, T Mirza, ... Oncogene 37 (3), 313-322, 2018 | 100 | 2018 |
